Page 13 of 16
ACS Medicinal Chemistry Letters
1
2
3
4
(8)
Cornford, P.; Evans, J.; Dodson, A.; Parsons, K.; Woolfenden, A.; Neoptolemos, J.; Foster, C. S.
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am. J. Pathol.
999, 154, 137-144.
9) Villar, J.; Arenas, M. I.; MacCarthy, C. M.; Blanquez, M. J.; Tirado, O. M.; Notario, V.
PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a Protein Kinase Cδ-
Dependent Mechanism. Cancer Res. 2007, 67, 10859-10868.
1
(
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
(10)
Antal, C. E.; Hudson, A. M.; Kang, E.; Zanca, C.; Wirth, C.; Stephenson, N. L.; Trotter, E. W.;
Gallegos, L. L.; Miller, C. J.; Furnari, F. B.; Hunter, T.; Brognard, J.; Newton, A. C. Cancer-Associated Protein
Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor. Cell (Cambridge, MA, United States) 2015,
1
60, 489-502.
(11)
Pandian, S. S.; Sneddon, A. A.; Bestwick, C. S.; McClinton, S.; Grant, I.; Wahle, K. W. J.; Heys,
S. D. Fatty Acid regulation of protein kinase C isoforms in prostate cancer cells. Biochem. Biophys. Res.
Commun. 2001, 283, 806-812.
(12)
apoptosis in human prostatic carcinoma cells. Exp. Cell Res. 1996, 224, 189-99.
13) Lamm, M. L. G.; Long, D. D.; Goodwin, S. M.; Lee, C. Transforming growth factor-β1 inhibits
membrane association of protein kinase Cα in a human prostate cancer cell line, PC3. Endocrinology 1997,
38, 4657-4664.
14) Fujii, T.; Garcia-Bermejo, M. L.; Bernabo, J. L.; Caamano, J.; Ohba, M.; Kuroki, T.; Li, L.; Yuspa,
Rusnak, J. M.; Lazo, J. S. Downregulation of protein kinase C suppresses induction of
(
1
(
S. H.; Kazanietz, M. G. Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis
in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. J. Biol. Chem. 2000, 275, 7574-82.
(15)
Kharait, S.; Dhir, R.; Lauffenburger, D.; Wells, A. Protein kinase Cdelta signaling downstream
of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem. Biophys. Res.
Commun. 2006, 343, 848-56.
(
16)
Wilding, G.; Verma, A. K. Protein Kinase Cε interacts with signal transducers and activators of transcription
(Stat3), phosphorylates Stat3 Ser727, and regulates its constitutive activation in Prostate cancer. Cancer
Res. 2007, 67, 8828-8838.
17) Gundimeda, U.; Schiffman, J. E.; Chhabra, D.; Wong, J.; Wu, A.; Gopalakrishna, R. Locally
Aziz, M. H.; Manoharan, H. T.; Church, D. R.; Dreckschmidt, N. E.; Zhong, W.; Oberley, T. D.;
3
(
Generated Methylseleninic Acid Induces Specific Inactivation of Protein Kinase C Isoenzymes: relevance to
selenium-induced apoptosis in prostate cancer cells. J. Biol. Chem. 2008, 283, 34519-34531.
(18)
Sarveswaran, S.; Gautam, S. C.; Ghosh, J. Wedelolactone, a medicinal plant-derived
coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε
without inhibiting Akt. Int. J. Oncol. 2012, 41, 2191-2199.
(19)
Sarveswaran, S.; Thamilselvan, V.; Brodie, C.; Ghosh, J. Inhibition of 5-lipoxygenase triggers
apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim. Biophys. Acta,
Mol. Cell Res. 2011, 1813, 2108-2117.
(20)
BinHafeez, B.; Zhong, W.; Fischer, J. W.; Mustafa, A.; Shi, X.; Meske, L.; Hong, H.; Cai, W.;
Havighurst, T.; Kim, K. M.; Verma, A. K. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-
naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an
orthotopic xenograft mouse model. Mol. Oncol. 2013, 7, 428-439.
(21)
Gobbi, G.; Mirandola, P.; Carubbi, C.; Micheloni, C.; Malinverno, C.; Lunghi, P.; Bonati, A.;
Vitale, M. Phorbol ester-induced PKCε down-modulation sensitizes AML cells to TRAIL-induced apoptosis
and cell differentiation. Blood 2009, 113, 3080-3087.
(22)
Schaar, D.; Goodell, L.; Aisner, J.; Cui, X. X.; Han, Z. T.; Chang, R.; Martin, J.; Grospe, S.; Dudek,
L.; Riley, J.; Manago, J.; Lin, Y.; Rubin, E. H.; Conney, A.; Strair, R. K. A phase I clinical trial of 12- O-
tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother.
Pharmacol. 2006, 57, 789-795.
(23)
Han, Z. T.; Tong, Y. K.; He, L. M.; Zhang, Y.; Sun, J. Z.; Wang, T. Y.; Zhang, H.; Cui, Y. L.;
Newmark, H. L.; Conney, A. H.; Chang, R. L. 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced increase
1
3
ACS Paragon Plus Environment